Table 1.
Characteristics of the sample in their final survey year, by cessation of smoke exposure (N=3,633)
| Total N=3,633 |
Cessation of Exposure | ||||
|---|---|---|---|---|---|
| Never N=784 (21.6%) |
Intermittent N=1,412 (38.9%) |
Permanent N=1,437 (39.6%) |
p-value1 | ||
| SOCIODEMOGRAPHIC | |||||
| Age at entry 2 | 7.7 (4.8) | 10.1 (5.0) | 5.9 (3.9) | 8.15 (4.7) | <0.001 |
| Female sex, % | 48.2 | 44.5 | 48.7 | 49.6 | 0.062 |
| Race/ethnicity, % | |||||
| White non-Hispanic | 83.5 | 84.1 | 85.8 | 80.9 | |
| Non-White non-Hispanic | 8.7 | 8.9 | 7.9 | 9.3 | 0.004 |
| Hispanic | 7.8 | 7.0 | 6.3 | 9.7 | |
| Household size | 4.3 (1.6) | 4.4 (1.6) | 4.3 (1.6) | 4.2 (1.5) | 0.195 |
| Household income, in $10K | 4.9 (3.2) | 4.5 (3.3) | 4.6 (3.3) | 5.4 (3.5) | <0.001 |
| Father’s education, % | |||||
| Less than high school | 6.7 | 8.0 | 6.3 | 6.1 | |
| High school | 40.6 | 47.1 | 42.8 | 34.8 | |
| Some college | 23.7 | 21.7 | 25.4 | 23.3 | <0.001 |
| College | 29.0 | 23.2 | 25.5 | 35.8 | |
| Health insurance type, % | |||||
| Private | 26.6 | 22.1 | 22.6 | 32.9 | |
| Public | 63.5 | 67.8 | 67.6 | 57.2 | |
| Private and Public | 8.7 | 8.4 | 8.7 | 8.9 | <0.001 |
| None/other | 1.2 | 1.7 | 1.1 | 1.0 | |
| CLINICAL | |||||
| Pulmonary exacerbations in 12 mos. | 0.8 (1.4) | 0.8 (1.4) | 0.9 (1.5) | 0.7 (1.4) | 0.004 |
| One or more, % | 39.1 | 40.0 | 41.6 | 36.5 | 0.019 |
| Two or more, % | 19.5 | 18.9 | 21.9 | 17.4 | 0.009 |
| BMI percentile | 50.7 (28.8) | 49.3 (29.3) | 50.3 (28.7) | 51.8 (28.6) | 0.137 |
| ppFEV1 | 84.6 (21.5) | 83.2 (21.3) | 84.2 (21.2) | 85.7 (21.6) | 0.026 |
| Genotype, % | |||||
| Heterozygous | 49.7 | 46.8 | 51.2 | 49.9 | |
| Homozygous | 37.1 | 37.9 | 37.2 | 36.7 | 0.106 |
| Other | 13.1 | 15.3 | 11.6 | 13.4 | |
| Newborn screening, % | 29.1 | 27.9 | 29.7 | 29.1 | 0.690 |
| CFTR modulator use, % | |||||
| Ivacaftor | 8.3 | 8.3 | 8.1 | 8.4 | 0.944 |
| Lumacaftor-ivacaftor | 9.3 | 7.5 | 11.0 | 8.6 | 0.014 |
| P. aeruginosa, % | |||||
| None | 67.1 | 67.6 | 66.9 | 67.5 | |
| Non-mucoid | 14.8 | 14.7 | 14.8 | 14.9 | 0.991 |
| Mucoid | 17.9 | 17.7 | 18.3 | 17.7 | |
| B. cepacia, % | 2.3 | 2.2 | 3.1 | 1.5 | 0.015 |
1
Significance level for the difference between those who experienced cessation and those who never experienced cessation.
2
Continuous measures are shown as mean (standard deviation).